Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Septerna Inc. shares soared as much as 42% in their trading debut after the biotechnology company raised $288 million in an ...

Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Septerna stock has risen 29%, to $23.31, since it debuted on the exchange Friday. The San Francisco biotechnology company said Thursday it would sell 16 million shares at $18 apiece, giving the ...

Goldman Sachs-backed Septerna would be valued around $750 million. Drug developers have achieved resounding success in the ...

Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is ...

The gross proceeds from the offering are expected to be $288.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small ...

Global stocks were trading higher on Friday, although they were set for a weekly loss amid US election jitters, while oil ...

Boeing is exploring the sale of its space business, the Wall Street Journal reported on Friday, citing people familiar with ...